Blog Layout

Research Explained – Structural and Enzymological Evidence for an Altered Substrate Specificity in Okur-Chung Neurodevelopmental Syndrome Mutant CK2αLys198Arg

Jennifer Sills • May 04, 2022

Link to Paper: https://doi.org/10.3389/fmolb.2022.831693


Authors: Werner C, Gast A, Lindenblatt D, Nickelsen A, Niefind K, Jose J, and Hochscherf J


Research Explained By: Dr. Jennifer Hochscherf


Research Explained Summary:


Patients with OCNDS have a change or mutation in the gene that contains the blueprint for the protein “protein kinase CK2alpha”. There are always two copies of this gene in the cell and the mutation only occurs in one of them. The blueprint determines the sequence in which different building blocks, so-called amino acids, are linked together in a long chain. However, this long chain should not be thought of as a straight thread, but rather it takes on a spatial three-dimensional structure that is determined by the sequence of the building blocks. This three-dimensional structure is crucial for the function of proteins.


The protein CK2alpha is an enzyme, a protein kinase to be more specific. Enzymes are tools of the cell to assist and catalyze chemical reactions. The CK2alpha reaction is the chemical modification of a second protein (the so-called “substrate protein”) by attachment of a phosphate group. This “phosphorylation” event is a metabolic signal with several possible consequences for the substrate protein: for example, it can be switched on or off, it can be marked for degradation or for transport to a specific location within the cell. In summary: correct and carefully out-balanced cellular phosphorylation reactions by CK2alpha and other protein kinases are crucial events to keep cells healthy and beneficial for the whole organism.


CK2alpha can phosphorylate different substrate proteins, and it recognizes them by a specific amino acid sequence on their surface. It is most important that this recognition works well and that the substrate proteins of CK2alpha are not mixed up with those of other protein kinases. To assist this job, CK2alpha has a binding partner called CK2beta. Together, they form a stable complex, the so-called CK2 holoenzyme, which in total consists of two CK2alpha and two CK2beta proteins and which is the predominant form in the cell.


In our research, funded by the CSNK2A1 foundation, we aimed to elucidate the consequences of the most common mutation reported for OCNDS patients, which leads to the exchange of the amino acid lysine at position 198 to arginine in CK2alpha (CK2α Lys198Arg ). We therefore examined several aspects of the CK2α Lys198Arg variant, such as the subunit interaction, stability, three-dimensional structure and activity and compared them with the non-mutated form, the “wild type”. We found that the mutation does not affect the interaction with CK2beta, and that the thermal stability of the protein is even slightly increased.


We applied a technique called X-ray crystallography that enables to determine and visualize the three-dimensional structure of a protein with near to atomic resolution to investigate the molecular details of the CK2α Lys198Arg structure. The mutated position 198 is located in the substrate recognition site of CK2alpha that exposes a positively charged surface area and preferentially binds negatively charged residues of its substrate proteins. In a CK2alpha X-ray structure solved in the absence of a substrate protein, the positively charged region is often occupied by two negatively charged sulfate ions. These sulfate ions thus mark the binding sites for negatively charged amino acid building blocks in the substrate protein that belong to the sequence recognized by CK2alpha. The most striking feature of the CK2α Lys198Arg structure is that the position of one of the characteristic sulfate ions is shifted compared to the wild-type. Although this shift of the anion binding site seems subtle at first sight, this structural finding supports the conclusion drawn by Caefer et al. (2022) that the CK2alpha mutant Lys198Arg does not primarily lead to a loss of function, but to a change in substrate specificity.


To detect possible selectivity changes due to the Lys198Arg mutation, comprehensive enzymatic activity assays have been performed in Prof. Joachim Jose’s research group at the University of Münster, Germany. The outcome of these assays support the conclusion by Caefer et al. (2022) that the substrate spectra of CK2α Lys198Arg and wild-type CK2alpha differ from each other, meaning that CK2α Lys198Arg has some substrate proteins not phosphorylated by wild-type CK2alpha and vice versa. In particular proteins of the nervous system might be differentially phosphorylated by the variant CK2α Lys198Arg and the wild-type form.


Understanding the molecular basis of OCDNS is important to identify the direction in which research should continue and ultimately to develop strategies for the development of therapies.


Link to: Caefer et al. (2022) The Okur-Chung Neurodevelopmental Syndrome Mutation CK2K198R Leads to a Rewiring of Kinase Specificity. Frontiers in Molecular Biosciences. https://doi.org/10.3389/fmolb.2022.850661




If you have any further questions, please contact Jennifer Sills at jennifer@csnk2a1foundation.org



Jennifer Hochscherf


I received my PhD in biochemistry from the University of Cologne in 2009 on the molecular interactions of CK2 and subsequently joined the laboratory of Prof. David Litchfield at the University of Western Ontario in London, Canada as a postdoctoral fellow. I then returned to Cologne to the laboratory of Prof. Karsten Niefind as a postdoc, with interruptions as an experienced researcher at the company Kinase Detect in Odense, Denmark and as a lecturer at the University of Cologne.


Since my PhD thesis, my research is focused on the protein kinase CK2. Currently, my focus is on the characterization of CK2alpha and CK2beta variants associated with the neurodevelopmental disorders OCNDS and POBINDS. I am particularly interested in the 3D structures of proteins and the biophysical characterization of protein-protein interactions as well as the interaction of proteins with small molecules.

FAQS RESOURCES REGISTER DONATE
Newborn Genetic Screenings

The Power of Newborn Genetic Screenings: How Newborn Genetic Screenings Can Change the Diagnosis

By Penelope Gatlin • 05 Oct, 2023
By Penelope Gatlin October 2023 When our son was born in 2012, he was hypotonic, severely jaundiced, had feeding difficulties and features such as epicanthic folds and small low set ears. We were told immediately that doctors had suspicions of a genetic syndrome. At that time, genetic testing was limited and once abnormal karyotype, Trisomy 21, and Fragile X were ruled out, we left the hospital with an 8 day old and no diagnosis. While no testing was available at that time to identify the ultra-rare syndrome my child had, because it wouldn’t even be identified until 4 years later, I can only imagine the difference it would have made to our journey to have such an answer sooner. Instead, we were unprepared and actually unaware that just because a diagnosis hadn’t been made then that it didn’t mean there wasn’t in fact a rare disease present. Instead, we dealt with issues as they came and worried and wondered what would be next. From feeding issues and reflux and constipation, to low muscle tone and delayed walking, to speech delay, social and emotional delays, toileting delays, diagnoses of developmental delay, anxiety, situational mutism, sensory processing disorder, and autism, until finally genetic testing that revealed the diagnosis that we’d waited 7 years to find out. While receiving a diagnosis can seem scary, not having an answer but knowing there must be one is even more so. In 2019, the day I clicked onto the portal to see the test results, the largest word on the page was POSITIVE. My heart stopped for a second. For the first time, I read the words “Okur-Chung Neurodevelopmental Disorder.” A roller coaster of emotions ensued, including sadness that we hadn’t known this from birth because it would have made us as parents more prepared, and given us more understanding about what might arise next. Relief that we had an answer, grateful that this syndrome had been identified and that he was among one of the first hundred diagnosed with it in the world, and glad we had the privilege to have access to the testing. Excitement that we can participate in future research. Fright that there’s so much we don’t know about OCNDS, and happiness that there is something that we do. A feeling that we are no longer shooting in the dark and have a small but supportive community to rely on and learn from. I am hopeful that one day, all newborns with features like my child will be tested at birth, so parents can have access to the answers, support, and interventions and therapies that can best help their child as soon as possible.
Autism Diagnosis

Why I Should Have Gotten the Autism Diagnosis for My Child Early On (or Why I Did Not)

By Terri Jordan • 23 Aug, 2023
For 16 years, my child displayed numerous symptoms that left us searching for answers, but a genetic diagnosis remained elusive. I considered having my child evaluated for autism to shed light on their situation. However, when I reached out to teachers, doctors, and therapists, I received frustrating responses: “Your child is too friendly to be autistic.” This statement made me doubt the possibility of autism because my child was sociable. “Your child can transition from one activity to another – they are not autistic.” Hearing this, I questioned whether my child’s ability to shift activities invalidated the need for an autism evaluation. “Your child can look me in the eye and answer questions – they are not autistic.” Observations like this made me second-guess the idea of autism, even though my child faced various challenges. “Getting a diagnosis that does not apply to your child would be a big waste of money.” Despite my persistent concerns, this cautionary advice about the evaluation costs left me hesitant. We finally pursued an evaluation when my son turned 20, and it confirmed that he is indeed on the autism spectrum (severe side). Looking back, I regret not taking this step sooner. I should have pursued the autism diagnosis before we received the genetic diagnosis. There are several benefits we could have gained as a family if we had pursued an early diagnosis: “Early Support Is Crucial:” I now realize that early intervention could profoundly impact my child’s development. We could have accessed the right services and therapies much earlier with a diagnosis. “Understanding My Child Better:” I struggled to comprehend my child’s behaviors and communication difficulties. An earlier diagnosis could have provided insights into their unique needs and thought processes. The education could also help me explain how to react to my child’s behavior to family members. “Tailored Guidance and Resources:” A diagnosis could have opened doors to specialized resources and guidance, enabling me to provide the best possible support for my child. “Connecting with Others:” Being part of the autism community might have connected us with other parents who understand our experiences. Sharing and learning from each other could have been invaluable. “Planning for the Future:” Knowing more about my child’s strengths and challenges could have helped me better plan their future, including education, career, and overall well-being. Depending on your location, many states offer funding and support if your child has an autism diagnosis. I wish I listened to my voice instead of being swayed by experts who didn’t fully understand my child’s situation. Ultimately, I know this decision is significant, requiring careful consideration by parents. Looking back, I wish I had trusted my instincts and sought an evaluation sooner to improve my child’s life.
Share by: